ANN ARBOR–Esperion Therapeutics Inc. (NASDAQ: ESPR) and Daiichi Sankyo Europe GmbH, the Europe-based organization of the Japanese pharmaceutical company Daiichi Sankyo Co. Ltd., announced a $125 million amendment to their collaboration, which includes an amicable resolution to their commercial dispute and other adjustments to enhance the long-term value of their products.